share_log

Clearmind Medicine | EFFECT: Others

Clearmind Medicine | EFFECT: Others

Clearmind Medicine | EFFECT：其他
SEC announcement ·  03/25 18:03
牛牛AI助理已提取核心訊息
Clearmind Medicine Inc., a company listed in the United States, has received a Notice of Effectiveness from the Securities and Exchange Commission (SEC) on March 22, 2024. The notice, identified by Accession Number 0001213900-24-024410 and Submission Type POS AM, signifies that the company's filing has been formally accepted by the SEC. The effectiveness of the filing, associated with File Number 333-276913, is a critical step in the regulatory process for Clearmind Medicine Inc.
Clearmind Medicine Inc., a company listed in the United States, has received a Notice of Effectiveness from the Securities and Exchange Commission (SEC) on March 22, 2024. The notice, identified by Accession Number 0001213900-24-024410 and Submission Type POS AM, signifies that the company's filing has been formally accepted by the SEC. The effectiveness of the filing, associated with File Number 333-276913, is a critical step in the regulatory process for Clearmind Medicine Inc.
在美國上市的公司Clearmind Medicine Inc. 已於2024年3月22日收到美國證券交易委員會（SEC）的生效通知。該通知以加入號0001213900-24-024410和提交類型爲POS AM標識，表示該公司的申請已被美國證券交易委員會正式接受。該文件編號爲333-276913，其有效性是Clearmind Medicine Inc.監管程序中的關鍵一步。
在美國上市的公司Clearmind Medicine Inc. 已於2024年3月22日收到美國證券交易委員會（SEC）的生效通知。該通知以加入號0001213900-24-024410和提交類型爲POS AM標識，表示該公司的申請已被美國證券交易委員會正式接受。該文件編號爲333-276913，其有效性是Clearmind Medicine Inc.監管程序中的關鍵一步。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。